Have a personal or library account? Click to login
Factors influencing vitamin K antagonists therapy / Factori care influențează terapia cu antagoniști ai vitaminei K Cover

Factors influencing vitamin K antagonists therapy / Factori care influențează terapia cu antagoniști ai vitaminei K

Revista Romana de Medicina de Laborator
Volume 23 (2015): Issue 2 (June 2015)
By: Ioana Brudașcă  
Open Access
|Jun 2015

References

  1. 1. Paterson JM, Mamdani M, Juurlink DN, Naglie G, Laupacis A, Stukel TA. Clinical consequences of generic warfarin substitution: an ecological study. JAMA. 2006; 296:1969-72. DOI: 10.1001/jama.296.16.1969-b10.1001/jama.296.16.1969-b17062858
    Search in Google Scholar
  2. 2. Borobia AM, Lubomirov R, Ramírez E, Lorenzo A, Campos A, Mu-oz-Romo R, et al. An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease. PLoS One. 2012;7(7):e41360. DOI: 10.1371/ journal.pone.004136010.1371/journal.pone.0041360340117222911785
    Search in Google Scholar
  3. 3. Gadisseur APA, van der Meer FJM, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol. 2002 Jun;117(4):940-6. DOI: 10.1046/j.1365-2141.2002.03493.x10.1046/j.1365-2141.2002.03493.x12060134
    Search in Google Scholar
  4. 4. Poller L. Interrnational Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2:849-60. DOI: 10.1111/j.1538-7836.2004.00775.x10.1111/j.1538-7836.2004.00775.x15140114
    Search in Google Scholar
  5. 5. Biss TT, Avery PJ, Walsh PM, Kamali F. Comparison of ‚time within therapeutic INR range’ with ‚percentage INR within therapeutic range’ for assessing longterm anticoagulation control in children. J Thromb Haemost. 2011;9:1090-2. DOI: 10.1111/j.1538-7836.2011.04500.x10.1111/j.1538-7836.2011.04500.x21899719
    Search in Google Scholar
  6. 6. Gatt A, Van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost. 2008;100:350-5. DOI: 10.1160/th07-05-035710.1160/TH07-05-0357
    Search in Google Scholar
  7. 7. Gatt A, Riddel A, Van Veen JJ, Kitchen S, Tuddenham EG, Makris M. Optimizing warfarin reversal - an ex vivo study. J Thromb Haemost. 2009;7(7):1123-7. DOI: 10.1111/j.1538-7836.2009.03435.x10.1111/j.1538-7836.2009.03435.x19575759
    Search in Google Scholar
  8. 8. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e44S-e88S.10.1378/chest.11-2292327805122315269
    Search in Google Scholar
  9. 9. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167(3):229-35. DOI: 10.1001/archinte.167.3.22910.1001/archinte.167.3.22917296877
    Search in Google Scholar
  10. 10. Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25(12):1801-8. DOI: 10.1592/phco.2005.25.12.180110.1592/phco.2005.25.12.180116305299
    Search in Google Scholar
  11. 11. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853-60. DOI: 10.1002/pds.155610.1002/pds.1556
    Search in Google Scholar
  12. 12. Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977;4(3):315-20. DOI: 10.1111/ j.1365-2125.1977.tb00719.x10.1111/j.1365-2125.1977.tb00719.x
    Search in Google Scholar
  13. 13. Gurwitz JH, Avorn J,Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the Anticoagulant Response to Warfarin Therapy. Ann Intern Med. 1992;116(11):901-4. DOI: 10.7326/0003-4819-116-11-90110.7326/0003-4819-116-11-901
    Search in Google Scholar
  14. 14. El-Helou N, Al-Hajje A, Ajrouche R, Awada S, Rachidi S, Zein S, et al. Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. Vasc Health Risk Manag. 2013;9:81-8.
    Search in Google Scholar
  15. 15. Martin JH. Pharmacogenetics of warfarin - is testing clinically indicated? Aust Prescr. 2009;32:76-80.
    Search in Google Scholar
  16. 16. Shibata Y, Hashimoto H, Kurata C, Ohno R, Kazui T, Takinami M. Influence of physical activity on warfarin therapy. Thromb Haemost. 1998; 80(1):203-4.
    Search in Google Scholar
  17. 17. Lenz TL, Lenz NJ, Faulkner MA. Potential interactions between exercise and drug therapy. Sports Med. 2004;34(5):293-306. DOI: 10.2165/00007256-200434050-0000210.2165/00007256-200434050-00002
    Search in Google Scholar
  18. 18. Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health. 1999;23(1):40-54.
    Search in Google Scholar
  19. 19. Booth SL, Suttie JW. Dietary Intake and Adequacy of Vitamin K. J Nutr. 1998;128(5):785-8.10.1093/jn/128.5.785
    Search in Google Scholar
  20. 20. Booth SL, Pennington JAT, Sadowski JA. Food sources and dietary intakes of vitamin K1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. J Am Diet Assoc. 1996;96:149-54. DOI: 10.1016/ S0002-8223(96)00044-210.1016/S0002-8223(96)00044-2
    Search in Google Scholar
  21. 21. Price R, Fenton S, Shearer MJ, Bolton-Smith C. Daily and seasonal variation in phylloquinone (vitamin K1) intake in Scotland. Proc Nutr Soc. 1996;55:244.
    Search in Google Scholar
  22. 22. Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007;5:2043-8. DOI: 10.1111/j.1538-7836.2007.02715.x10.1111/j.1538-7836.2007.02715.x17666020
    Search in Google Scholar
  23. 23. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109:2419-23. DOI: 10.1182/ blood-2006-09-04926210.1182/blood-2006-09-04926217110451
    Search in Google Scholar
  24. 24. de Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE, Improved Oral Anticoagulation After a Dietary Vitamin K-Guided Strategy. A Randomized Controlled Trial. Circulation. 2009;120:1115-22. DOI: 10.1161/CIRCULATIONAHA.109.84920810.1161/CIRCULATIONAHA.109.84920819738137
    Search in Google Scholar
  25. 25. Beatty SJ, Mehta BH, Rodis JL. Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. Ann Pharmacother. 2005;39(4):744-7. DOI: 10.1345/aph.1E45410.1345/aph.1E45415755790
    Search in Google Scholar
  26. 26. Hornsby LB, Hester EK, Donaldson AR. Potential interaction between warfarin and high dietary protein intake. Pharmacotherapy. 2008;28(4):536-9. DOI: 10.1592/phco.28.4.53610.1592/phco.28.4.536
    Search in Google Scholar
  27. 27. Paoletti A, Gallo E, Benemei S, Vietri M, Alfredo Vannacci, et al. Interactions between Natural Health Products and Oral Anticoagulants: Spontaneous Reports in the Italian Surveillance System of Natural Health Products. Evidence-Based Complementary and Alternative Medicine 2011(2011), Article ID 612150, 5 pages.
    Search in Google Scholar
  28. 28. Olson RE. Vitamin K. In: Shils M, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Lippincott Williams & Wilkins. 1999:363-80.
    Search in Google Scholar
  29. 29. Traber MG. Vitamin E and K interactions-a 50-yearold problem. Nutr Rev. 2008;66(11):624-9. DOI: 10.1111/j.1753-4887.2008.00123.x10.1111/j.1753-4887.2008.00123.x
    Search in Google Scholar
  30. 30. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2010;30(1):110.
    Search in Google Scholar
  31. 31. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs. Pharmacotherapy 2004;24:1668-74. DOI: 10.1592/ phco.24.17.1668.5233810.1592/phco.24.17.1668.52338
    Search in Google Scholar
  32. 32. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy 2003;23(1):109-12. DOI: 10.1592/ phco.23.1.109.3191310.1592/phco.23.1.109.31913
    Search in Google Scholar
  33. 33. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am. 1992;6(6):1247-57.10.1016/S0889-8588(18)30273-9
    Search in Google Scholar
  34. 34. Sawicka-Powierza J, Rogowska-Szadkowska D, Ołtarzewska AM, Chlabicz S. Factors influencing activity of oral anticoagulants. Interactions with drugs and food. Pol Merkur Lekarski. 2008;24(143):458-62.
    Search in Google Scholar
  35. 35. Rettie A, Tai G. Pharmacogenomics of warfarin metabolism. Molecular Interventions. 2006;6(4):223-7. DOI: 10.1124/mi.6.4.810.1124/mi.6.4.8
    Search in Google Scholar
  36. 36. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11(9):803-8. DOI: 10.1097/00008571-200112000-0000810.1097/00008571-200112000-00008
    Search in Google Scholar
  37. 37. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006;16(7):497-514. DOI: 10.1097/01. fpc.0000215069.14095.c610.1097/01
    Search in Google Scholar
  38. 38. Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther. 2007;29(3):427-37. DOI: 10.1016/S0149-2918(07)80081-610.1016/S0149-2918(07)80081-6
    Search in Google Scholar
  39. 39. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation of warfarin dose. N Engl J Med. 2005;352:2285-93. DOI: 10.1056/NEJMoa04450310.1056/NEJMoa04450315930419
    Search in Google Scholar
  40. 40. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41. DOI: 10.1038/nature0221410.1038/nature0221414765194
    Search in Google Scholar
  41. 41. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticogulant effect of warfarin. Blood. 2005 Jan 15;105(2):645-9. DOI: 10.1182/ blood-2004-06-211110.1182/blood-2004-06-211115358623
    Search in Google Scholar
  42. 42. Sinxadi P, Blockman M. Warfarin resistance. Cardiovasc J Afr. 2008;19(4):215-7.
    Search in Google Scholar
  43. 43. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res. 2007;5:8-16. DOI: 10.3121/cmr.2007.72410.3121/cmr.2007.724185534017456829
    Search in Google Scholar
  44. 44. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-33. DOI: 10.1182/ blood-2005-03-110810.1182/blood-2005-03-110815947090
    Search in Google Scholar
  45. 45. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 Oct;90(4):625-9. DOI: 10.1038/ clpt.2011.18510.1038/clpt.2011.185318755021900891
    Search in Google Scholar
  46. 46. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med. 2013;369:2294-303. DOI: 10.1056/NEJMoa131138610.1056/NEJMoa131138624251363
    Search in Google Scholar
  47. 47. Stergiopoulos K, Brown DL. Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues Meta- analysis of Randomized Clinical Trials. JAMA Intern Med. 2014;174(8):1330-8. DOI: 10.1001/jamainternmed. 2014.2368
    Search in Google Scholar
  48. 48. Bauer KA. Pros and cons of new oral anticoagulants. ASH Education Book. 2013;2013(1):464-70. DOI: 10.1182/asheducation-2013.1.464 10.1182/asheducation-2013.1.46424319220
    Search in Google Scholar
DOI: https://doi.org/10.1515/rrlm-2015-0015 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 159 - 167
Submitted on: Feb 10, 2015
Accepted on: May 15, 2015
Published on: Jun 23, 2015
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Vitamin K antagonists,
warfarin,
drug interactions,
genotyping CYP2C9,
VKORC1
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2015 Ioana Brudașcă, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 23 (2015): Issue 2 (June 2015)Next article